Brokerages predict that BioScrip, Inc. (NASDAQ:BIOS) will announce earnings of ($0.10) per share for the current quarter, Zacks reports. Four analysts have issued estimates for BioScrip’s earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.09). BioScrip posted earnings per share of ($0.09) in the same quarter last year, which would indicate a negative year-over-year growth rate of 11.1%. The company is scheduled to report its next quarterly earnings results on Monday, November 6th.

On average, analysts expect that BioScrip will report full-year earnings of ($0.55) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.54). For the next fiscal year, analysts forecast that the business will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.18) to ($0.13). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow BioScrip.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). The firm had revenue of $218.11 million during the quarter, compared to analyst estimates of $220.05 million. The business’s quarterly revenue was down 6.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.14) earnings per share.

A number of analysts have recently issued reports on BIOS shares. Zacks Investment Research raised BioScrip from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Wednesday, July 5th. BidaskClub lowered BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. SunTrust Banks, Inc. raised BioScrip from a “hold” rating to a “buy” rating and lifted their target price for the stock from $3.25 to $3.75 in a research report on Thursday, August 10th. Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 target price (up from $3.00) on shares of BioScrip in a research report on Thursday, August 10th. Finally, ValuEngine raised BioScrip from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $3.75.

In related news, Director Coliseum Capital Management, L sold 2,846,941 shares of BioScrip stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $2.93, for a total value of $8,341,537.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.80% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Gilder Gagnon Howe & Co. LLC boosted its stake in BioScrip by 248.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock valued at $41,298,000 after acquiring an additional 10,845,410 shares during the period. FMR LLC boosted its stake in BioScrip by 10.8% in the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock valued at $14,453,000 after acquiring an additional 520,231 shares during the period. Vanguard Group Inc. boosted its stake in BioScrip by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock valued at $12,204,000 after acquiring an additional 146,980 shares during the period. Wynnefield Capital Inc. boosted its stake in BioScrip by 2.7% in the first quarter. Wynnefield Capital Inc. now owns 3,800,000 shares of the company’s stock valued at $6,460,000 after acquiring an additional 100,000 shares during the period. Finally, Alta Fundamental Advisers LLC boosted its stake in BioScrip by 36.9% in the second quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock valued at $8,240,000 after acquiring an additional 818,000 shares during the period. Institutional investors own 84.05% of the company’s stock.

BioScrip (NASDAQ:BIOS) opened at 2.69 on Tuesday. BioScrip has a 52-week low of $0.98 and a 52-week high of $3.43. The stock’s 50 day moving average price is $2.87 and its 200 day moving average price is $2.28. The firm’s market capitalization is $342.91 million.

ILLEGAL ACTIVITY NOTICE: “Brokerages Expect BioScrip, Inc. (BIOS) to Announce -$0.10 Earnings Per Share” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/19/brokerages-expect-bioscrip-inc-bios-to-announce-0-10-earnings-per-share.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.